Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.
Kjetil BoyeAlessandra LonghiTormod GurenSusanne LorenzStine NæssMichela PieriniIngeborg TaksdalIngvild LobmaierMarilena CesariAnna PaioliAyca M LøndalenElisabetta SetolaIvar HomplandLeonardo A Meza-ZepedaKirsten Sundby HallEmanuela PalmeriniPublished in: Cancer immunology, immunotherapy : CII (2021)
In this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.